Role of Artificial Intelligence in PET/CT Imaging for Management of Lymphoma

Semin Nucl Med. 2023 May;53(3):426-448. doi: 10.1053/j.semnuclmed.2022.11.003. Epub 2023 Mar 3.

Abstract

Our review shows that AI-based analysis of lymphoma whole-body FDG-PET/CT can inform all phases of clinical management including staging, prognostication, treatment planning, and treatment response evaluation. We highlight advancements in the role of neural networks for performing automated image segmentation to calculate PET-based imaging biomarkers such as the total metabolic tumor volume (TMTV). AI-based image segmentation methods are at levels where they can be semi-automatically implemented with minimal human inputs and nearing the level of a second-opinion radiologist. Advances in automated segmentation methods are particularly apparent in the discrimination of lymphomatous vs non-lymphomatous FDG-avid regions, which carries through to automated staging. Automated TMTV calculators, in addition to automated calculation of measures such as Dmax are informing robust models of progression-free survival which can then feed into improved treatment planning.

Publication types

  • Review
  • Research Support, N.I.H., Intramural

MeSH terms

  • Artificial Intelligence
  • Fluorodeoxyglucose F18
  • Humans
  • Lymphoma* / diagnostic imaging
  • Lymphoma* / therapy
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography

Substances

  • Fluorodeoxyglucose F18